STX 0712
Alternative Names: STX-0712Latest Information Update: 07 Jan 2025
Price :
$50 *
At a glance
- Originator Solu Therapeutics
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Antibody-dependent cell cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Acute myeloid leukaemia; Chronic myelomonocytic leukaemia
Most Recent Events
- 09 Dec 2024 Pharmacodynamics data from preclinical studies in Acute myeloid leukemia and Chronic myelomonocytic leukaemia released by Solu Therpaeutics
- 02 Dec 2024 Preclinical trials in Acute myeloid leukaemia in USA (unspecified route)
- 02 Dec 2024 Preclinical trials in Chronic myelomonocytic leukaemia in USA (unspecified route)